Dr Mafalda Oliveira speaks to ecancer as part of SABCS 2022 about her study that looked at camizestrant compared with fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer.

She explains that patients were randomised between two different doses of camizestrant and fulvestrant (the current standard of care).

Dr Oliveira reports that both doses of camizestrant were superior to fulvestrant in terms of progression free survival.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть